about
Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculationIncreased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutationIntegrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis.Blast phase of essential thrombocythemia: A single center study.Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisPrognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.Somatic mutations of calreticulin in myeloproliferative neoplasms.Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasmsJAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.Clinical significance of somatic mutation in unexplained blood cytopenia.Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasmsmiRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.Germline RBBP6 mutations in familial myeloproliferative neoplasms.Cord blood in vitro expanded CD41 cells: identification of novel components of megakaryocytopoiesis.Allelic imbalance in CALR somatic mutagenesis.Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.Clinical significance of genetic aberrations in secondary acute myeloid leukemia.Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.Mutations and prognosis in primary myelofibrosis.Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders.The JAK2 V617F mutation in patients with cerebral venous thrombosis.Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis.Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.
P50
Q24307864-E5DADE94-D1BA-4992-975C-10A90FF22ECAQ28222209-E333C3F1-1300-4C4F-A979-28ED1F00E6F5Q31019526-B585AA57-FAAB-4644-9CF6-7482C8D066FBQ33385885-76686187-8ED2-4AFD-B68E-99C3D1BC3F1EQ33416223-22774FAF-C370-475C-A8AC-855A7697ED97Q33432755-8515ABAE-7E97-4908-A67E-E8FA93B8B3C7Q33440477-D46A69D8-4347-4AF3-862C-494AEEFA617AQ34039270-86DBAA2C-7A42-4B6D-89EC-0D4CD6629427Q34106883-1A91A611-6333-4C10-8EDA-4051B9A69600Q34750599-5F981DED-F3D3-496B-A80D-25C4722F8E10Q35023429-E360BE47-6234-41A8-875D-23D83C3DC8BFQ35925679-3E812F38-2104-48CC-919B-BCDBA5DA6B4BQ36541323-464F1588-2C20-459A-96D4-BD49B5B096B8Q36576138-A47B3F1A-124F-4F4F-9BB5-A528F3791637Q36873306-7F85CCF1-A9DF-43C5-B1AD-A370763F422EQ37623539-5DA6ECBA-3E4F-4D31-8368-BC6BBA3A1A3DQ38220788-2C86A565-2151-4C3B-9FB7-34B8125F5C4DQ38329285-6F3B3362-7731-48C8-ABA0-C127F9F0A694Q39275658-F1FC2CE1-9F52-429F-B693-D00234C19993Q39869997-7961F3CF-FAC6-4C68-9720-3396912679F9Q39918869-FD046D9F-8E85-4DFD-8489-4FE01656B069Q41240561-FA68638B-B97F-4FA1-9BF0-54B585B91151Q42033175-6FDD906B-0F3D-41AA-8C5F-C8FA17654FC3Q42073825-390491D2-D8E7-436D-8A53-72352FFC27EAQ42082695-B9BC83B9-9A44-4972-BF55-A86831E6D412Q42389394-0D7A0DDF-BEB3-4532-94C1-3E7C18AB6D8CQ42493815-DCC3ADD9-6813-49B2-A88E-D48586A5EB12Q42556934-753BBFF0-3FB5-4318-BEDB-236F066E89EFQ42639007-30A37503-3851-4E3D-8925-1AC9A60E5D82Q42758710-0C0EEEDF-DBE0-44E0-ACBD-B76647EDD640Q43405916-788844DF-8BB5-470C-A225-8754FFAE4A75Q43898090-557C8FBE-4D6E-45DE-8AB5-35C903865C79Q44302357-EABB0209-3082-4E7A-AEC0-5B1DCD01A1FDQ44429606-FA90CFCF-6865-4673-BBDF-5E982BF720EEQ45028996-566359B7-790A-4BB1-B7DC-2269958EE2CAQ45878282-5C4FAE66-7BA4-4C8E-9086-0A2949081B37Q46366679-26350254-6DC3-4004-84EE-76E0F6C59D13Q46889570-99B33952-A68E-4DDE-8651-3BE0EBC5FB70Q46913469-E9DB0528-8B7C-4ED9-8414-E5ADC52B381EQ46960830-BF8F8EFD-2C84-468A-8D82-AFD409F0161D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Daniela Pietra
@ast
Daniela Pietra
@en
Daniela Pietra
@es
Daniela Pietra
@fr
Daniela Pietra
@nl
Daniela Pietra
@sl
type
label
Daniela Pietra
@ast
Daniela Pietra
@en
Daniela Pietra
@es
Daniela Pietra
@fr
Daniela Pietra
@nl
Daniela Pietra
@sl
prefLabel
Daniela Pietra
@ast
Daniela Pietra
@en
Daniela Pietra
@es
Daniela Pietra
@fr
Daniela Pietra
@nl
Daniela Pietra
@sl
P1053
F-3931-2016
P106
P1153
35562732200
P21
P31
P3829
P496
0000-0002-6575-8766